The ROSI study (risedronate in adults with osteogenesis imperfecta type 1)

Podobne zapisy

• The ROSI study (Risedronate in adults with osteogenesis imperfecta type 1): Improved BMD but high fracture rate persists.
  od: Bradbury, L, i wsp.
  Wydane: (2006)
• Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
  od: Bradbury, L, i wsp.
  Wydane: (2012)
• Calcitonin in osteogenesis imperfecta.
  od: Smith, R, i wsp.
  Wydane: (1973)
• Cardiovascular abnormalities in osteogenesis imperfecta.
  od: White, N, i wsp.
  Wydane: (1983)
• Valuation of lost productivity of adults with X-linked Hypophosphataemia and Osteogenesis imperfecta
  od: Cole, S, i wsp.
  Wydane: (2023)